Login / Signup

Anakinra as first-line monotherapy for new-onset steroid-naïve sJIA patients.

Maria Vincenza MastroliaSarah Abu-RumeilehIlaria MaccoraValerio ManiscalcoEdoardo MarraniIlaria PagniniAndrea TaddioGabriele Simonini
Published in: Expert review of clinical immunology (2024)
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • prognostic factors
  • randomized controlled trial
  • clinical trial